What is the Purpose of this Study?
This study focuses on individuals who have a primary central nervous system (CNS) tumor and are planning to undergo surgery to remove the tumor. The purpose of the study is to examine the investigational use of a drug called tozuleristide and the Canvas imaging system device during surgical resection (removal) of primary CNS tumors. Researchers aim to determine whether the use of tozuleristide and the Canvas imaging system may be useful in assisting clinical decision-making during surgery. Participants will receive 1 dose of tozuleristide before their planned surgery, during which the Canvas imaging system device will be used. The device attaches to a surgical microscope and is used to detect fluorescence (shining) of the study drug (tozuleristide), which helps identify CNS tumors and distinguish them from nearby normal tissue such as brain and nerves.
Eligibility
- * MRI obtained within 30 days of study enrollment documents a measurable lesion consistent with a primary malignant central nervous system tumor for which maximal safe resection is indicated OR MRI obtained within 30 days of study enrollment documents a measurable lesion consistent with a primary schwannoma enhancing tumor in the cerebellopontine angle for which maximal safe resection is indicated.
- * Adequate renal and liver function
- * Subjects with prior therapy are eligible provided they have recovered from any acute toxic effects of prior therapy and have sufficient time interval prior to enrollment.
Where can I participate?
CS Cancer at Cedars-Sinai Medical Center
More about this Clinical Trial
What is the full name of this clinical trial?
IIT2020-09-Yu-BBIST001: A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged with the Canvas System